Replies to post #118902 on Biotech Values

[DewDiligence]

If ABT and BIIB merge, they can figure this out amicably :- )

[genisi]

Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.